NeoGraph Analytics
PharmaceuticalsNorth America2023 – 2032

Intravenous Iron Drugs Market Size, Share and Trends Analysis

Global intravenous iron drugs market valued at $1.22B in 2023, projected to reach $1.92B by 2032 with 5.8% CAGR. Key drivers include rising anemia prevalence and treatment advancements. Download full market analysis report.

Revenue, 2023

$1.2B

Forecast, 2032

$1.9B

CAGR, 2024-2032

5.8%

Report Coverage

North America

Code: intravenous-iron-drugs-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The global intravenous iron drugs market is experiencing steady growth, driven by rising anemia prevalence and treatment advancements, with a projected CAGR of 5.8% from 2024 to 2032.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Increasing adoption in chronic kidney disease managementShift from oral to intravenous iron therapyEmergence of next-generation iron formulations with improved safety profilesRising healthcare expenditure in emerging economies
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 5.8%

Base Year (2023)

$1.3B

Forecast (2032)

$1.9B

CAGR (2024-2032)

5.8%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 45.2%CAGR: 4.9%

Largest market: United States

Europe

#2
Share: 30.1%CAGR: 5.3%

Largest market: Germany

03

Market Dynamics

  • Rising prevalence of iron deficiency anemia globally
  • Advancements in IV iron formulations with better tolerability
  • Expanding indications for IV iron in chronic diseases
  • Aging populations and increased comorbidity rates
04

Market Segmentation

By Application

  • Chronic Kidney Disease
  • Cancer-Related Anemia
  • Postpartum Anemia
  • Inflammatory Bowel Disease
  • Other

By End User

  • Hospitals
  • Specialized Clinics
  • Ambulatory Surgical Centers
  • Other
05

Regional Analysis

1

North America

Lead: United States
CAGR: 4.9%Share: 45.2%

The largest regional market due to advanced healthcare infrastructure, high anemia prevalence, and established reimbursement frameworks, with the U.S. accounting for over 90% of North American sales.

2

Europe

Lead: Germany
CAGR: 5.3%Share: 30.1%

Germany and the UK lead adoption due to robust healthcare systems and national anemia management guidelines, with increasing IV iron use in chronic disease settings.

3

Asia Pacific

Lead: China
CAGR: 7.2%Share: 24.7%

Fastest-growing region driven by rising healthcare expenditure, expanding chronic disease burden, and increasing awareness of IV iron therapy, particularly in China and India.

Country-Level Analysis

CountryShareGrowth
United States
25.1%
+4.5%
Germany
10.3%
+5.0%
China
8.5%
+7.5%
06

Competitive Landscape

A

Amgen

United States

Leader30.5B

Dominant player with Feraheme, focusing on oncology and CKD applications with strong clinical evidence and global distribution network.

Feraheme
R

Roche

Switzerland

Leader64.5B

Market leader in iron sucrose (Venofer) with extensive hospital penetration and ongoing R&D for pediatric indications.

Venofer
V

Vifor Pharma

Switzerland

Challenger1.5B

Major player with Venofer and Ferric Carboxymaltose, expanding into emerging markets and developing novel formulations.

VenoferFerric Carboxymaltose
F

Fresenius Kabi

Germany

Challenger

Leading supplier of iron sucrose with strong hospital relationships and cost-effective manufacturing capabilities.

G

Grunenthal

Germany

Follower

Focused on specialty formulations for niche applications including postpartum anemia and inflammatory conditions.

07

Recent Developments

25
2025Amgen

Launched Feraheme in expanded pediatric indications for CKD-related anemia following FDA approval

24
2024Vifor Pharma

Received FDA approval for Venofer in postpartum anemia, targeting a new patient population

24
2024Fresenius Kabi

Expanded iron sucrose manufacturing capacity in response to Asia Pacific demand growth

24
2024Roche

Initiated Phase III trial for Venofer in cancer-related anemia with reduced infusion time

23
2023Grunenthal

Secured EMA approval for new iron isomaltoside formulation with enhanced safety profile

08

Regulatory Landscape

FDA's 2023 safety guidelines for IV iron administration in chronic kidney diseaseEMA's 2024 review of adverse event reporting protocols for IV iron productsMHRA's 2023 updated recommendations for hypersensitivity risk management
09

Frequently Asked Questions

The market was valued at $1.22 billion in 2023 and is projected to reach $1.92 billion by 2032.
The market is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2032.
Iron sucrose holds the largest market share at 35.2%, driven by its established safety profile in chronic kidney disease.
Asia Pacific is the fastest-growing region with a projected CAGR of 7.2%, fueled by rising chronic disease burden and healthcare investment.